Andreas Tiede: PK-Guided Approaches for Recombinant Porcine Factor VIII in Acquired Hemophilia
Andreas Tiede, Professor in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post on LinkedIn:
“Dosing of Obizur — recombinant porcine factor VIII — can be challenging due to short half-life in bleeding patients with acquired haemophilia. You can read about our experience with PK-guided continuous infusion and bolus dosing in an upcoming JTH article.”
Read the full article here .
Title: Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A
Authors: Justus Heeg, Christiane Dobbelstein, Alfonso Iorio, Heiko Schenk, Benjamin Seeliger, Andreas Tiede

Stay updated on the latest scientific advancements with Hemostasis Today.
-
Jul 11, 2026, 11:31Acute DVT Management and the Role of Interventions Beyond Anticoagulation: Insights From ISTH 2026
-
Jul 11, 2026, 09:48International Collaboration in Antithrombotic Stewardship – Anticoagulation Forum
-
Jul 11, 2026, 09:45Presenting New CRP-A Data at ISTH 2026 – Pplus Medical Limited
-
Jul 11, 2026, 09:41David Smadja: Addressing the Hidden Threat of Medical Misinformation at ISTH 2026
-
Jul 11, 2026, 09:40Dianne E. van der Wal: The Latest Advances in Hemostasis and Thrombosis on First Day of ISTH 2026
-
Jul 11, 2026, 09:34Heading to ISTH 2026 in Paris Join our session on patient led VTE education – NBCA
-
Jul 11, 2026, 09:33Flora Peyvandi: Empowering the Next Generation of ISTH
-
Jul 11, 2026, 09:28Ruah Alyamany: Surgical and Procedural Bleeding Risk – Perioperative AC guidance
-
Jul 11, 2026, 09:24Habib Bennaceur: New Perspectives on Patient-Centered Hemophilia Care at ISTH 2026